Castle Biosciences (CSTL) News Today $21.51 +0.25 (+1.18%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$21.54 +0.04 (+0.16%) As of 04/17/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Castle Biosciences (NASDAQ:CSTL) Trading Up 4.7% - Should You Buy?Castle Biosciences (NASDAQ:CSTL) Stock Price Up 4.7% - Time to Buy?April 17 at 4:35 PM | marketbeat.comPortolan Capital Management LLC Has $20.70 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Portolan Capital Management LLC lessened its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 38.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 776,579 shares of the company's stock after selling 479,049 shApril 16 at 8:10 AM | marketbeat.comRenaissance Technologies LLC Has $18.26 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Renaissance Technologies LLC boosted its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 39.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 685,000 shares of the company's stock aApril 15 at 4:27 AM | marketbeat.comExodusPoint Capital Management LP Sells 32,779 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)ExodusPoint Capital Management LP cut its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 74.1% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 11,484 shares of the company's stock after selling 32,779 shareApril 15 at 3:40 AM | marketbeat.comCastle Biosciences: Steady Revenue Stream, But Medicare Reimbursement Loss A ConcernApril 14, 2025 | seekingalpha.com28,903 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Acquired by Arrowstreet Capital Limited PartnershipArrowstreet Capital Limited Partnership bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 28,903 shares of the coApril 14, 2025 | marketbeat.comVanguard Group Inc. Has $48.84 Million Stake in Castle Biosciences, Inc. (NASDAQ:CSTL)Vanguard Group Inc. increased its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 4.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,832,535 shares of the company's stock after purchApril 14, 2025 | marketbeat.comDynamic Technology Lab Private Ltd Sells 26,264 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Dynamic Technology Lab Private Ltd reduced its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 59.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,630 shares of the company's stock afApril 11, 2025 | marketbeat.comAmerican Century Companies Inc. Has $1.84 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)American Century Companies Inc. boosted its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 28.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,175 sharesApril 10, 2025 | marketbeat.comBrokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) Target Price at $38.75April 10, 2025 | americanbankingnews.comWellington Management Group LLP Purchases Shares of 722,120 Castle Biosciences, Inc. (NASDAQ:CSTL)Wellington Management Group LLP acquired a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 722,120 shares of the company's stock, valued at approximately $1April 9, 2025 | marketbeat.comCastle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative PartnershipsApril 8, 2025 | globenewswire.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by BrokeragesShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The aveApril 8, 2025 | marketbeat.comCastle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive YearApril 7, 2025 | globenewswire.comCastle Biosciences, Inc. (NASDAQ:CSTL) Stock Holdings Increased by Trexquant Investment LPTrexquant Investment LP boosted its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 27.5% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 203,571 shares of the company's stock after purchasing an additionaApril 7, 2025 | marketbeat.comCastle Biosciences announces publication of papers on DecisionDx-Melanoma testApril 4, 2025 | markets.businessinsider.comPublication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences' DecisionDx®-Melanoma TestApril 3, 2025 | globenewswire.comAre Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?April 2, 2025 | finance.yahoo.comCastle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with MelanomaApril 1, 2025 | globenewswire.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 1,236 SharesCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 1,236 shares of Castle Biosciences stock in a transaction on Wednesday, March 26th. The shares were sold at an average price of $20.30, for a total value of $25,090.80. Following the completion of the transaction, the insider now owns 77,099 shares in the company, valued at $1,565,109.70. This represents a 1.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.March 29, 2025 | marketbeat.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 1,236 Shares of StockMarch 29, 2025 | insidertrades.comCastle Biosciences price target lowered to $30 from $37 at GuggenheimMarch 28, 2025 | markets.businessinsider.comCastle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk GroupsMarch 28, 2025 | globenewswire.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Acquired by EntryPoint Capital LLCEntryPoint Capital LLC raised its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 214.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 29,144 shares of the company's stock after acquiring an aMarch 26, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Position Trimmed by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. trimmed its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 5.8% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 258,866 shares of the company's stock after seMarch 24, 2025 | marketbeat.comCastle Biosciences management to meet with StephensMarch 21, 2025 | markets.businessinsider.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Buy" by AnalystsCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) has received a consensus rating of "Buy" from the seven ratings firms that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that havMarch 13, 2025 | marketbeat.comDerek J. Maetzold Sells 2,130 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,130 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $19.52, for a total value of $41,577.60. Following the completion of the transaction, the insider now owns 78,335 shares in the company, valued at $1,529,099.20. The trade was a 2.65 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.March 12, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $455,496.68 in StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 22,639 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $20.12, for a total transaction of $455,496.68. Following the sale, the insider now directly owns 80,465 shares in the company, valued at $1,618,955.80. This represents a 21.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.March 12, 2025 | marketbeat.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 2,130 Shares of StockMarch 12, 2025 | insidertrades.comLisanti Capital Growth LLC Cuts Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Lisanti Capital Growth LLC lessened its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 70.1% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 46,265 shares of the company's stock after selling 108,445 shares during the quarter. Lisanti Capital GMarch 8, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Down 3.8% - Should You Sell?Castle Biosciences (NASDAQ:CSTL) Shares Down 3.8% - Here's What HappenedMarch 6, 2025 | marketbeat.comSolid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A BusinessMarch 6, 2025 | finance.yahoo.comCastle Biosciences (CSTL) Gets a Buy from ScotiabankMarch 4, 2025 | markets.businessinsider.comLeerink Partnrs Weighs in on CSTL Q1 EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2026 EPS estimates for Castle Biosciences in a research report issued to clients and investors on Friday, February 28th. Leerink Partnrs analyst P. Souda expects that the company will earn ($0March 3, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Gap Up Following Analyst UpgradeCastle Biosciences (NASDAQ:CSTL) Shares Gap Up Following Analyst UpgradeMarch 1, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Given New $37.00 Price Target at Robert W. BairdRobert W. Baird lifted their price objective on shares of Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a report on Friday.March 1, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Posts Quarterly Earnings Results, Beats Expectations By $0.36 EPSCastle Biosciences (NASDAQ:CSTL - Get Free Report) posted its earnings results on Thursday. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.36. Castle Biosciences had a return on equity of 1.47% and a net margin of 1.95%.February 28, 2025 | marketbeat.comCastle Biosciences price target raised to $37 from $36 at BairdFebruary 28, 2025 | markets.businessinsider.comCastle Biosciences sees FY25 revenue $280M-$295M, consensus $269.06MFebruary 27, 2025 | markets.businessinsider.comCastle Biosciences, Inc. (CSTL) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comCastle Biosciences, Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 27, 2025 | seekingalpha.comCastle Biosciences Reports Fourth Quarter and Full-Year 2024 ResultsFebruary 27, 2025 | businesswire.comWhat To Expect From Castle Biosciences Inc (CSTL) Q4 2024 EarningsFebruary 26, 2025 | finance.yahoo.comCastle Biosciences to Participate in Upcoming Investor ConferencesFebruary 25, 2025 | businesswire.comPrincipal Financial Group Inc. Has $38.26 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. decreased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,435,665 shares of the company'sFebruary 22, 2025 | marketbeat.com73,500 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by Hussman Strategic Advisors Inc.Hussman Strategic Advisors Inc. bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 73,500 shares of the company's stock, valued at approximately $1,9February 21, 2025 | marketbeat.comCastle Biosciences (CSTL) Expected to Announce Earnings on ThursdayCastle Biosciences (NASDAQ:CSTL) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=663251)February 20, 2025 | marketbeat.comKornitzer Capital Management Inc. KS Has $10.23 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Kornitzer Capital Management Inc. KS lessened its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 5.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 383,974 shares of the company's stock after selling 23,264 shares during the qFebruary 19, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Buy" from AnalystsShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average tFebruary 16, 2025 | marketbeat.com Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Media Mentions By Week CSTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼0.960.49▲Average Medical News Sentiment CSTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼84▲CSTL Articles Average Week Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Progyny News Addus HomeCare News Ardent Health Partners News National HealthCare News PACS Group News Teladoc Health News AdaptHealth News Viridian Therapeutics News CareDx News Aveanna Healthcare News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredThey Won’t Tell You This About GoldInflation, digital currency, and government policy are quietly eating away at your savings — and most people w...American Alternative | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
